Department of Medicine, Surgery and Dentistry "Scuola Medica Salernitana", University of Salerno, Baronissi, 84081 Salerno, Italy.
Clinical Pharmacology, University Hospital "San Giovanni di Dio e Ruggi D'Aragona", 84131 Salerno, Italy.
Int J Mol Sci. 2021 Jan 12;22(2):705. doi: 10.3390/ijms22020705.
Bone marrow failure (BMF) syndromes are a heterogenous group of non-malignant hematologic diseases characterized by single- or multi-lineage cytopenia(s) with either inherited or acquired pathogenesis. Aberrant T or B cells or innate immune responses are variously involved in the pathophysiology of BMF, and hematological improvement after standard immunosuppressive or anti-complement therapies is the main indirect evidence of the central role of the immune system in BMF development. As part of this immune derangement, pro-inflammatory cytokines play an important role in shaping the immune responses and in sustaining inflammation during marrow failure. In this review, we summarize current knowledge of cytokine signatures in BMF syndromes.
骨髓衰竭(BMF)综合征是一组异质性的非恶性血液疾病,其特征是单一或多谱系细胞减少症(s),具有遗传或获得性发病机制。异常的 T 或 B 细胞或固有免疫反应在 BMF 的病理生理学中各不相同,并且在标准免疫抑制或抗补体治疗后血液学改善是免疫系统在 BMF 发展中起核心作用的主要间接证据。作为这种免疫失调的一部分,促炎细胞因子在塑造免疫反应和维持骨髓衰竭期间的炎症中起着重要作用。在这篇综述中,我们总结了 BMF 综合征中细胞因子特征的现有知识。